Behind The Scenes Of Pharma Mergers And Acquisitions - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Behind The Scenes Of Pharma Mergers And Acquisitions


Pharmaceutical Technology Europe
Volume 22, Issue 9

In summary


The author says…
It is likely that a new round of mergers and acquisitions are set to take place in the pharmaceutical industry. Although such tie-ups can improve pipelines in the short-term and improve marketing potential, many of the mergers are also influenced by pressure from outside parties who believe bigger organisations will provide better financial return to investors. The financial effort required for the next round of mergers among the top ten companies will need to be huge. As has already been seen, targeted companies tend to hold out for improved offers rather than accept an initial approach. Takeovers will have to be planned meticulously since companies will need to determine how they borrow the billions of dollars required, absorb the costs involved and yet still deliver on their promises to investors.

References

1. KPMG, "Global M&A: Outlook for Pharmaceuticals" (2009). http://www.kpmgeuropellp.eu/

2. Chemistry World, "Pharma's year of merger mania" (2009). http://www.rsc.org/

3. A. Pollack, "Roche Agrees to Buy Genentech for $46.8 Billion" (2009). http://www.nytimes.com/

4. Drug, Discovery & Development, "Roche Leaves PhRMA" (2009). http://www.dddmag.com/

5. Wall Street Journal, "Pharmaceutical Merger Bonanza: $500 Million of Fees in 3 Months" (2009). http://blogs.wsj.com/

6. R. Breitman, "Pharma Mergers Boom Despite Global Credit Woes" (2008). http://www.law.com/

7. Anon, "King Completes Acquisition of Alpharma. King Pharmaceuticals" (2008). http://www.kingpharm.com/

8. A. Pollack, "Genentech Urges a Rebuff to Roche" (2009). http://www.nytimes.com/

9. S. Cage, "Roche seen upping $42 billion Genentech bid after rebuff" (2009). http://www.reuters.com/

10. Anon, "Roche and Genentech reach a friendly agreement to combine the two organizations and create a leader in healthcare innovation" (2009). http://www.roche.com/

11. T. Staton, "Merger costs weigh on Pfizer, Roche" (2010). http://www.fiercepharma.com/

12. L. Johnson, "Pfizer CEO: Wyeth Merger Will Bring What's Needed" (2010). http://www.dddmag.com/

13. Wall Street Journal, "Checking the Math on Job Cuts at Pfizer and Wyeth" (2009). http://blogs.wsj.com/

14. E. Silverman, "Merck And Pfizer Plan 900 Job Cuts" (2010). http://www.pharmalot.com/

15. R. Waters, "Genentech culture intact after Roche takeover" (2010). http://articles.sfgate.com/

16. T. Staton, "Sanofi isn't alone in eyeing Genzyme deal" (2010). http://www.fiercepharma.com/


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology Europe,
Click here